The major advances in the treatment for chronic lymphocytic leukemia (CLL) over the past decade are targeted oral drugs: BTK inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib, and the BCL-2 inhibitor venetoclax, often combined with an anti-CD20 antibody. These agents have largely replaced chemoimmunotherapy for most patients. Newer options, including a non-covalent BTK inhibitor and CAR T-cell therapy, now extend control for disease that has relapsed after both drug classes.
This guide is written for clinicians and trainees, but patients and families will find the principles useful when discussing choices with their hematologist. It covers diagnosis, when to start treatment, the current drug classes, and how therapy is sequenced.
CLL at a Glance
CLL is one of the most common types of leukemia in adults, particularly in older people, and is more frequent in men. It is a clonal proliferation of mature-appearing B lymphocytes that accumulate in the blood, lymph nodes, spleen, and the bone marrow.
Many patients are diagnosed incidentally when a routine blood count shows lymphocytosis. Others present with lymphadenopathy, splenomegaly, fatigue, recurrent infections, or B symptoms (fever, drenching night sweats, and unintentional weight loss).
Diagnostic criteria
The diagnosis requires at least 5 × 10⁹/L clonal B lymphocytes in the peripheral blood, sustained for at least three months. Flow cytometry confirms the typical immunophenotype: CD5, CD19, and CD23 positive, with dim CD20 and dim surface immunoglobulin restricted to a single light chain. A marrow biopsy is not required for diagnosis, although it helps evaluate unexplained cytopenias.
Staging and Prognostic Markers
Two clinical staging systems remain in daily use. They rely only on examination and a blood count, which makes them simple and reproducible.
| Rai stage | Defining feature | Binet stage | Defining feature |
|---|---|---|---|
| 0 | Lymphocytosis only | A | Fewer than three enlarged lymphoid areas |
| I | Plus enlarged lymph nodes | B | Three or more enlarged lymphoid areas |
| II | Plus enlarged spleen or liver | C | Hemoglobin below 10 g/dL or platelets below 100 × 10⁹/L |
| III | Hemoglobin below 11 g/dL | ||
| IV | Platelets below 100 × 10⁹/L |
Before any treatment, guidelines recommend testing for del(17p) and TP53 mutation and determining IGHV mutation status. TP53 aberrations predict poor response to chemotherapy, and unmutated IGHV predicts shorter remissions after chemoimmunotherapy. Both results steer the choice between targeted regimens. Because TP53 status can change as the disease evolves, it is repeated before each new line of therapy.
When to Start Treatment
Early-stage, asymptomatic CLL is still managed with active monitoring (“watch and wait”). Starting treatment early in asymptomatic patients has not been shown to prolong survival, even with modern drugs.
Treatment is indicated when the disease is active, as defined by international (iwCLL) criteria:
- Progressive marrow failure with worsening anemia or thrombocytopenia
- Massive (at least 6 cm below the costal margin), progressive, or symptomatic splenomegaly
- Massive (at least 10 cm), progressive, or symptomatic lymphadenopathy
- Lymphocyte doubling time under six months
- Autoimmune anemia or thrombocytopenia poorly responsive to standard therapy
- Disease-related symptoms such as B symptoms or significant fatigue
An absolute lymphocyte count alone, however high, is not an indication to treat. For the broader context of how these decisions fit into leukemia care, see our overview of leukemia treatment options.
Current Targeted Therapies
BTK inhibitors
Bruton’s tyrosine kinase is a key enzyme in B-cell receptor signaling. Ibrutinib was the first covalent BTK inhibitor; the second-generation agents acalabrutinib and zanubrutinib are more selective and generally better tolerated, with less atrial fibrillation. These drugs are taken continuously until progression or intolerance. They are effective regardless of TP53 status, which makes them a preferred choice in high-risk disease.
Class effects to monitor include bleeding and bruising, atrial fibrillation, hypertension, infections, and arthralgia. Holding the drug around surgery and reviewing anticoagulants and antiplatelet agents is standard practice.
Venetoclax-based regimens
Venetoclax blocks BCL-2, an anti-apoptotic protein that CLL cells depend on. Its major advantage is fixed-duration therapy: venetoclax with obinutuzumab is given for about one year in the first-line setting, and venetoclax with rituximab for about two years in relapsed disease. Venetoclax combined with ibrutinib is another time-limited option in some regions.
The main risk is tumor lysis syndrome, so venetoclax is started with a five-week dose ramp-up, hydration, uric acid-lowering therapy, and laboratory monitoring guided by tumor burden. Neutropenia is common and is managed with dose interruptions or growth factor support.
Choosing between them
| Feature | Continuous BTK inhibitor | Fixed-duration venetoclax combination |
|---|---|---|
| Duration | Indefinite | About 12 to 24 months |
| Key toxicities | Bleeding, atrial fibrillation, hypertension | Tumor lysis syndrome, neutropenia, infusion reactions |
| Monitoring burden | Ongoing, lower intensity | Intensive during ramp-up, then time off treatment |
| Good fit for | Cardiac-safe patients, TP53-aberrant disease | Patients who value treatment-free intervals |
Measurable residual disease (MRD) testing is increasingly used to assess response depth after fixed-duration therapy.
Relapsed Disease and Newer Options
For disease progressing on a covalent BTK inhibitor, pirtobrutinib, a non-covalent BTK inhibitor, can remain active against common BTK resistance mutations. Patients who received fixed-duration venetoclax and had a long remission may be retreated with it.
CAR T-cell therapy (lisocabtagene maraleucel) is approved for relapsed or refractory CLL after both a BTK inhibitor and venetoclax. Allogeneic stem cell transplantation remains the only established curative approach and is reserved for fit patients with high-risk, multiply relapsed disease.
Clinicians should also watch for Richter transformation, the evolution of CLL into an aggressive lymphoma, usually diffuse large B-cell lymphoma. Rapidly enlarging nodes, a sharp rise in LDH, or new B symptoms warrant a biopsy.
Supportive Care and Key Takeaways
CLL causes immune dysfunction independent of treatment, including low immunoglobulins. Supportive care includes vaccinations (avoiding live vaccines), skin cancer screening, prompt treatment of infections, and immunoglobulin replacement for recurrent serious infections with hypogammaglobulinemia. Coordinating with primary care is central to managing hematological disorders in older adults with other illnesses. Our leukemia guide places CLL alongside the other leukemias.
- Targeted therapy with BTK inhibitors or venetoclax combinations is now standard first-line care for most patients.
- Test TP53 and IGHV status before each line of treatment.
- Treat only active disease as defined by iwCLL criteria.
- Pirtobrutinib, CAR T-cell therapy, and transplant are options after resistance to both main drug classes.
Frequently Asked Questions
Is chemoimmunotherapy still used for CLL?
Rarely. FCR (fludarabine, cyclophosphamide, rituximab) was once standard for young, fit patients with mutated IGHV, but targeted agents have largely replaced it because of better tolerability and efficacy across risk groups.
Can CLL be cured with the new drugs?
Targeted therapies provide long remissions but are not considered curative. Allogeneic stem cell transplant is the only established curative option, and it carries significant risks.
Why is CLL sometimes left untreated after diagnosis?
Early-stage CLL can remain stable for years, and early treatment in asymptomatic patients has not improved survival. Monitoring avoids drug side effects until treatment is actually needed.
What is the difference between ibrutinib and acalabrutinib?
Both block BTK, but acalabrutinib is more selective. It tends to cause fewer cardiac and bleeding side effects, while efficacy is broadly comparable.
